Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study-Reference-Cited by-同舟云学术

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

Published:2018-01-29 Issue:3 Volume:32 Page:397-402
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Reich K.¹,Gooderham M.²,Bewley A.³⁴,Green L.⁵,Soung J.⁶,Petric R.⁷,Marcsisin J.⁷,Cirulli J.⁷,Chen R.⁷,Piguet V.⁸⁹¹⁰

Affiliation:

1. Dermatologikum Hamburg and SCIderm Research Institute; Hamburg Germany

2. SKiN Centre for Dermatology; Queen's University and Probity Medical Research; Peterborough Ontario Canada

3. Whipps Cross University Hospital; London UK

4. The Royal London Hospital; London UK

5. George Washington University; School of Medicine; Washington DC USA

6. Southern California Dermatology; Santa Ana CA USA

7. Celgene Corporation; Summit NJ USA

8. Cardiff University and University Hospital of Wales; Wales UK

9. Division of Dermatology; Women's College Hospital; Toronto Ontario, Canada

10. Division of Dermatology; Department of Medicine; University of Toronto; Toronto Ontario, Canada

Funder

Celgene

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14738/fullpdf

Reference7 articles.

1. The efficacy and safety of apremilast, etanercept, and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE);Reich;J Eur Acad Dermatol Venereol,2017

2. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]);Papp;J Am Acad Dermatol,2015

3. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2);Paul;Br J Dermatol,2015

4. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis;Kavanaugh;J Rheumatol,2015

5. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial;Cutolo;J Rheumatol,2016

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12

2. Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments;Clinical, Cosmetic and Investigational Dermatology;2023-07

3. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis;Clinical and Experimental Dermatology;2023-04-13

4. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries;British Journal of Dermatology;2023-03-27

5. Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations;The Journal of Rheumatology;2022-11-01